Understanding how MAP2 affects nerve damage from chemotherapy
Official title: Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity
Funded at Mayo Clinic Rochester · NIH-11006261 · Data updated 2026-11-12
This study is looking at how a protein called MAP2 might help protect nerves from damage caused by chemotherapy drugs, which can lead to uncomfortable side effects for cancer patients, and it uses special lab techniques to better understand this process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $622,064 |
| NIH project number | 5R01CA275870-03 |
| Project ID | NIH-11006261 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving chemotherapy and experiencing symptoms of peripheral neuropathy.
✕Less likely to help
Patients who are not undergoing chemotherapy or do not experience peripheral neuropathy may not benefit from this research.
What this research studies
This research investigates the role of a protein called MAP2 in causing nerve damage related to chemotherapy, known as chemotherapy-induced peripheral neuropathy (CIPN). By using human-derived nerve cells, the researchers will explore how chemotherapy drugs like bortezomib, paclitaxel, and vincristine affect MAP2 levels and its localization within the cells. The study aims to understand the mechanisms behind nerve damage and how enhancing MAP2 levels could potentially protect against this side effect. This innovative approach includes using advanced genetic engineering techniques to create modified nerve cells for detailed analysis.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or reducing nerve damage in patients undergoing chemotherapy.
How similar studies have gone: Previous research has shown promising results in understanding nerve damage mechanisms related to chemotherapy, but this specific approach using MAP2 is novel.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Staff, Nathan P — Mayo Clinic Rochester
- Study coordinator: Staff, Nathan P
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.